Adult Vaccines Market Size, Share and Trends Analysis Report, By Vaccine Type (Monovalent and Multivalent), By Technology (Live Attenuated Vaccines, Bacterial Vaccines, Toxoid Vaccines, Recombinant Vaccines, and Conjugate Vaccines), Forecast (2022-2028)

The global adult vaccines market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The increasing prevalence of chronic diseases among adults and development of novel vaccine technologies are major factors to drive the global adult vaccines market. In addition, increased research in the field of vaccine technologies and increasing government support are also supporting in growth of the global adult vaccines market. For instance, in 2021, a portion of the subunit, recombinant, polysaccharide, and conjugate vaccine dominated the adult vaccine market due to these vaccines were reported to bring a strong immune response to almost everyone who needed it, including people with weakened immune systems and seasonal health problems.

Therefore, several government agencies provide funding and resources to expand research into specific vaccines to improve their effectiveness and disease control. In addition, some government agencies provide guidelines for their safe use. it’s the increased R&D investment in the pharmaceutical and biopharmaceutical industries and the wide range of R&D pipelines also have a strong positive impact on the global adult immunization market. Moreover, adult immunizations include the administration of an approved vaccine given to patients 18 years of age and older, for medical indications, and some vaccines are often used to treat infectious diseases among infants and children. However, the Centers for Disease Control & Prevention (CDC) also recommends that adults occasionally take vaccines, called adult vaccines.

Merck & Co., Inc., GlaxoSmithKline plc, Sanofi SA, Pfizer Inc., and AstraZeneca Plc. are the market players that are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches. Market players are increasingly focusing on developing vaccines that address diseases that are more likely to cause pandemics. For instance, in 2018, an Indian-based drug company, Cipla, in partnership with the Serum Institute of India, launched the Hepatitis B vaccine for adults in the country. The disease affects more than 40 million people in the country, according to India’s Global Immunization Program. In addition, Dynavax Technologies Corporation received FDA approval in 2019, with its two-dose Hepatitis-B vaccine prescribed for adults 18 years and older.

Market Coverage

  • The market number available for – 2021-2028
  • Base year- 2021
  • Forecast period- 2022-2028
  • Segment Covered-
    • By Vaccine Type
    • By Technology
  • Regions Covered-
    • North America
    • Europe
    • Asia-Pacific
    • Rest of the World
  • Competitive Landscape-Merck & Co., Inc., GlaxoSmithKline plc, Sanofi SA, Pfizer Inc., Johnson & Johnson service Ltd., and AstraZeneca Plc. among others.

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominate the market in the base year?
  • Which segment and region will project the fastest growth in the market?
  • How has COVID-19 impacted the market?
    • Deviation from the pre-COVID-19 forecast
    • Most affected region and segment
  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

Adult Vaccines Market Report by Segment

By Type

  • Monovalent
  • Multivalent

By Technology

  • Live Attenuated Vaccines
  • Bacterial Vaccines
  • Toxoid Vaccines
  • Recombinant Vaccines
  • Conjugate Vaccines

Adult Vaccines Market Report by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific

Rest of the World

  • Latin America
  • Middle East & Africa

The report will be delivered within 48-72 hours after payment confirmation